Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal. (2020). SKIN The Journal of Cutaneous Medicine, 4(6), s83. https://doi.org/10.25251/skin.4.supp.83